What Do Patients Know about Biosimilar Drugs?

Estándar

September 1, 2016 • By By Lisa Rapaport, Reuters Staff

The Rheumatologist

(Reuters Health)—Many patients haven’t heard of biosimilars, generic versions of complex biotech drugs, and even some who say they’re familiar with these medicines may still be confused about them, a small European survey suggests.

To see what patients know about biosimilars, researchers analyzed data from online surveys completed by 1,181 patients with irritable bowel disease or Crohn’s disease, which are often treated with biosimilars.

Overall, just 38 percent of the survey respondents had heard of biosimilars.

keep reading

Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in spain

Estándar

Joan M Nolla Manuel Rodríguez Emilio Martin-Mola Enrique Raya Isabel Ibero Gonzalo Nocea Belén Aragon Luis LIzán Miriam Prades

Patient Preference and Adherence 2016:10 1101–1113

Purpose: To de ne importance values assigned to attributes of biological agents (BAs) by Spanish patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and rheumatologists. Patients and methods: This was an observational, cross-sectional design based upon a rank- based full-pro le conjoint analysis. A literature review and four focus groups were undertaken to identify attributes and levels. An orthogonal matrix, combining the selected levels of attri- butes, was used to de ne scenarios. Participants ranked eight scenarios from 1 (most preferred) to 8 (least preferred). The relative importance (RI) of attributes was calculated. Multivariate regression analysis was performed to identify the characteristics that in uenced the values of RI. A total of 488 patients (male 50.9%, mean age 50.6 [standard deviation {SD} 12.06] years, rheumatoid arthritis 33.8%, ankylosing spondylitis 32.4%, psoriatic arthritis 33.8%; mean time since diagnosis 12.6 [SD 8.2] years) and 136 rheumatologists (male 50.4%, mean age 46.4 [SD 9.1] years, mean time of practice 16.7 [SD 8.8] years) participated. Results: The ideal BAs for patients and physicians, respectively, should allow pain relief and improvement of functional capacity (RI 39% and 44.7%), with low risk of adverse events (RI 24.9% and 30.5%), a long time prior to perceiving the need for a new dose (RI 16.4% and 12.4%), and self-administration at home (RI 19.7% and 12.5%), as identi ed through their preferences. Conclusion: Although ef cacy and safety are paramount for patients and rheumatologists to make a choice regarding BAs, the need for a low frequency of administration and the administration method also play a role as preference attributes for BAs. Keywords: preferences, conjoint analysis, attributes, biological agents, rheumatic diseases